NasdaqGS - Nasdaq Real Time Price USD

Madrigal Pharmaceuticals, Inc. (MDGL)

242.43 +6.27 (+2.66%)
As of 12:13 PM EDT. Market Open.
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Operating Expense
454,197.00
380,496.00
293,571.00
242,482.00
206,673.00
--
Operating Income
-454,197.00
-380,496.00
-293,571.00
-242,482.00
-206,673.00
--
Net Non Operating Interest Income Expense
9,922.00
6,866.00
-1,779.00
363.00
4,329.00
--
Other Income Expense
--
--
--
273.00
100.00
--
Pretax Income
-444,275.00
-373,630.00
-295,350.00
-241,846.00
-202,244.00
--
Net Income Common Stockholders
-444,275.00
-373,630.00
-295,350.00
-241,846.00
-202,244.00
--
Diluted NI Available to Com Stockholders
-444,275.00
-373,630.00
-295,350.00
-241,846.00
-202,244.00
--
Basic EPS
-23.14
--
-17.23
-14.63
-13.09
-5.45
Diluted EPS
-23.14
--
-17.23
-14.63
-13.09
-5.45
Basic Average Shares
19,141.19
--
17,137.20
16,535.19
15,446.64
15,394.66
Diluted Average Shares
19,141.19
--
17,137.20
16,535.19
15,446.64
15,394.66
Total Operating Income as Reported
-454,197.00
-380,496.00
-293,571.00
-242,482.00
-206,673.00
--
Total Expenses
454,197.00
380,496.00
293,571.00
242,482.00
206,673.00
--
Net Income from Continuing & Discontinued Operation
-444,275.00
-373,630.00
-295,350.00
-241,846.00
-202,244.00
--
Normalized Income
-444,275.00
-373,630.00
-295,350.00
-241,846.00
-202,244.00
--
Interest Income
24,136.00
19,578.00
2,185.00
363.00
4,329.00
--
Interest Expense
14,214.00
12,712.00
3,964.00
--
--
--
Net Interest Income
9,922.00
6,866.00
-1,779.00
363.00
4,329.00
--
EBIT
-430,061.00
-360,918.00
-291,386.00
-241,846.00
-206,673.00
--
EBITDA
-429,490.00
-360,391.00
-290,919.00
-241,441.00
-206,202.00
--
Reconciled Depreciation
571.00
527.00
467.00
405.00
471.00
--
Net Income from Continuing Operation Net Minority Interest
-444,275.00
-373,630.00
-295,350.00
-241,846.00
-202,244.00
--
Normalized EBITDA
-429,490.00
-360,391.00
-290,919.00
-241,441.00
-206,202.00
--
12/31/2019 - 2/6/2007

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

VKTX Viking Therapeutics, Inc.
61.20
-1.70%
 
CYTK Cytokinetics, Incorporated
49.55
+2.14%
 
AXSM Axsome Therapeutics, Inc.
74.53
+1.50%
 
IOVA Iovance Biotherapeutics, Inc.
8.61
-3.06%
 
AKRO Akero Therapeutics, Inc.
19.38
+2.98%
 
ALT Altimmune, Inc.
7.75
+3.20%
 
TGTX TG Therapeutics, Inc.
16.26
-0.25%
 
IMVT Immunovant, Inc.
25.98
+2.32%
 
VRNA Verona Pharma plc
12.16
+0.75%
 
JANX Janux Therapeutics, Inc.
55.00
+2.80%